selective D1-like receptor antagonist that has been studied clinically in humans in the treatment of a variety of conditions, including schizophrenia, cocaine abuse, obesity, pathological gambling, and Tourette's syndrome, with efficacy in some of these conditions seen. The drug produced mild-to-moderate, reversible depression and anxiety in clinical studies however and has yet to complete development for any indication. List of D1 receptor antagonists Benzazepine derivatives SCH-23,390 - 100-fold selectivity for D1 over D5 Ecopipam (SCH-39,166) - a selective D1/D5 antagonist that was being developed as an anti-obesity medication but was discontinued However, it has showed promise in reducing Stuttering and is currently in Phase 2 Trials for this purpose Modulators DETQ − PAM LY-3154207 – potent and subtype selective PAM, in phase 2 studies for Lewy body dementia. Protein–protein interactions Dopamine receptor D1 has been shown to interact with: COPG2, COPG, and DNAJC14. Receptor oligomers The D1 receptor forms heteromers with the following receptors: dopamine D2 receptor, dopamine D3 receptor, histamine H3 receptor, μ opioid receptor, NMDA receptor, and adenosine A1 receptor. D1–D2 receptor complex D1−H3−NMDAR receptor complex − a target to prevent neurodegeneration D1–D3 receptor complex D1–NMDAR receptor complex D1–A1 receptor complex Structure Several CryoEM structures of agonists bound to the dopamine D1 receptor complexed with the stimulatory heterotrimeric Gs protein have been determined. Agonist interact with extracellular loop 2 and extracellular regions of trans-membrane helices 2, 3, 6, and 7. Interactions between catechol-based agonists and three trans-membrane serine residues including S1985.42, S1995.43, and S2025.46 function as microswitches that are essential for receptor activation. See also Dopamine receptor References External links Dopamine receptors